Chronic idiopathic urticaria has a strong autoimmune component in a significant number of people who have it, though not in everyone. Current evidence suggests that up to 45% of cases are autoimmune in origin, meaning the immune system is directly attacking the body’s own cells to produce hives. The remaining cases arise from mechanisms that aren’t yet fully understood. So the short answer is: it’s not classified as a purely autoimmune disease, but autoimmunity is the leading explanation for roughly half of all cases.
The Name Change That Reflects New Understanding
If you’ve seen both “chronic idiopathic urticaria” (CIU) and “chronic spontaneous urticaria” (CSU) used interchangeably, that’s because they refer to the same condition. The medical community now prefers “chronic spontaneous urticaria” because the word “idiopathic” implies a complete mystery, while “spontaneous” better captures what’s actually happening: hives that appear without any external trigger, because the underlying problem is intrinsic. The condition is defined as hives lasting longer than six weeks, occurring on most days, with no identifiable external cause like a food allergy or physical stimulus.
This shift in terminology matters because it signals a shift in thinking. Rather than throwing up their hands at an unknown cause, researchers have increasingly identified the internal immune dysfunction driving the condition.
How Autoimmunity Triggers Hives
In the autoimmune subset of CSU, the body produces antibodies (a type called IgG) that target its own mast cells and a type of white blood cell called basophils. Specifically, about 40% of CSU patients have circulating antibodies directed at one of two targets: either IgE molecules sitting on the surface of these cells, or the high-affinity IgE receptor (the docking station where IgE attaches). Antibodies against the receptor are the more common of the two.
When these rogue antibodies bind to mast cells in the skin, they force the cells to dump their contents, primarily histamine, into surrounding tissue. This is the same chemical cascade that happens during an allergic reaction, but there’s no allergen involved. The immune system is essentially creating a false alarm. A landmark study demonstrated that serum from CSU patients could trigger histamine release from healthy donor blood cells, confirming that something circulating in the blood was directly causing the reaction.
The Thyroid Connection
One of the strongest pieces of evidence for autoimmunity in CSU is how frequently it overlaps with autoimmune thyroid disease. In one study, autoimmune thyroid disease was diagnosed in about 33% of CSU patients compared to just 5% of controls. Antibodies against thyroid proteins were dramatically more common: anti-thyroid peroxidase antibodies appeared in 51% of CSU patients versus 6% of controls, and anti-thyroglobulin antibodies in 42% versus 4%.
A large meta-analysis covering more than 14,000 CSU patients found they were five to seven times more likely to test positive for thyroid autoantibodies than the general population. Hypothyroidism was also far more prevalent, affecting about 28% of CSU patients compared to 4% of controls. This clustering of autoimmune conditions in the same patients strongly suggests a shared tendency toward immune dysregulation rather than coincidence.
Testing for the Autoimmune Subtype
There is a screening test called the autologous serum skin test (ASST) that can help identify whether your CSU has an autoimmune basis. The test involves drawing a small amount of your blood, separating the serum, and injecting it back into your skin. If a wheal (a raised, red bump) forms, it suggests your blood contains something, likely autoantibodies, that activates mast cells. The test has a sensitivity and specificity of roughly 70 to 80%, so it’s useful but not definitive. A positive result makes autoimmune CSU more likely, while a negative result doesn’t completely rule it out.
Who Gets It
CSU affects just under 1% of the U.S. population, with a diagnosed prevalence of about 0.78%. The average age at diagnosis is 37, and women are affected slightly more often than men, making up about 52% of cases. Nearly half of CSU patients also report having allergies, though allergies and the autoimmune mechanism behind CSU are distinct processes.
How It’s Treated
Treatment follows a stepwise approach. The first line is second-generation antihistamines (the non-drowsy kind), starting at standard doses and increasing up to four times the usual dose if symptoms persist. Many people get adequate relief at this stage, but a substantial portion don’t.
For antihistamine-resistant cases, the next step is omalizumab, an injectable medication originally developed for severe asthma. It works by binding to free IgE in the blood, preventing it from attaching to mast cells. Over time, this also reduces the number of IgE receptors on skin mast cells and basophils, essentially removing the targets that autoantibodies attack. In clinical trials, 300 mg every four weeks significantly reduced itch and wheal scores compared to placebo, with patients roughly 4.5 times more likely to achieve a complete response. In one real-world study, about 75% of patients achieved disease control by week 12. Some people respond after a single injection, while others need up to 24 weeks, and about half of initial non-responders at week 12 eventually respond by week 24.
If omalizumab doesn’t work, immunosuppressive therapy is the next option in guideline recommendations. Newer treatments targeting a specific signaling molecule inside mast cells and immune cells (called BTK) are in late-stage clinical trials. In phase 2 studies, these BTK inhibitors showed rapid and sustained improvement in disease activity, and they may become an important option for people who don’t respond to current therapies.
How Long It Lasts
CSU typically persists for three to five years on average, but individual variability is enormous. Published remission rates range from 10 to 38% at one year and 30 to 71% at five years. That wide spread reflects differences in study populations and definitions of remission, but the general trend is encouraging: the condition does resolve for most people over time, though it can take years. A minority of patients deal with it for a decade or longer. There’s currently no reliable way to predict at the outset how long your case will last, though researchers are working on predictive models using factors like disease severity and autoantibody status.